SCHEMBL284094

SCHEMBL284094

CCC(=O)c1ccc2cc(C(C)(C)C(F)(F)F)ccc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
PTPN1 P18031 6/20 0.42
HPGD P15428 4/20 0.39
KDM4E B2RXH2 1/20 0.39
ATM Q13315 1/20 0.39
MAPT P10636 3/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
TSHR P16473 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HSD17B10 Q99714 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
GSK3B P49841 1/20 0.36
ACHE P22303 1/20 0.36
HTT P42858 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL284052 0.87 HSD11B1 (0.42) ALDH1A1SMN1; SMN2NPC1RAB9APTPN1
SCHEMBL284008 0.84 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2NPC1RAB9APTPN1
SCHEMBL284015 0.83 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2NPC1RAB9APTPN1
SCHEMBL269267 0.81 PTPN1 (0.44) PTPN1ACHE
SCHEMBL21573033 0.80 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2NPC1RAB9APTPN1
SCHEMBL283862 0.77 SMN1; SMN2 (0.37) ALDH1A1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL4108411 0.74 SMN1; SMN2 (0.50) ALDH1A1SMN1; SMN2NPC1RAB9APTPN1
SCHEMBL30623333 0.73 SMN1; SMN2 (0.72) ALDH1A1SMN1; SMN2NPC1RAB9APTPN1
SCHEMBL15385104 0.73 KDM4E (0.56) ALDH1A1SMN1; SMN2NPC1RAB9APTPN1
SCHEMBL1317943 0.73 SMN1; SMN2 (0.72) ALDH1A1SMN1; SMN2NPC1RAB9APTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS OPRL1, CNR1, TRPV1 ALDH1A1 986/4885SMN1; SMN2 1166/4885NPC1 443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.